Support for involvement of the renin–angiotensin system in dysplastic Barrett’s esophagus

References

• Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Nat Cancer Inst. 2005;97:142–146.
   PubMed Web of Science ®Google Scholar
• Voutilainen M. Epidemiological trends in oesophageal cancer in the Nordic countries. Scand J Gastroenterol. 2008;43:323–327.
   PubMed Web of Science ®Google Scholar
• Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak?. Cancer Epidemiol Biomarkers Prev. 2010;19:1468–1470.
   PubMed Web of Science ®Google Scholar
• Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365:1375–1383.
   PubMed Web of Science ®Google Scholar
• Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63:7–42.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol.2003;35:881–900.
   PubMed Web of Science ®Google Scholar
• Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol. 1997;17:467–491.
   PubMed Web of Science ®Google Scholar
• Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metabol. 2005;16:293–299.
   PubMed Web of Science ®Google Scholar
• Sjoberg T, Garcia Rodriguez LA, Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin Gastroenterol Hepatol. 2007;5:1160–1166.
   PubMed Web of Science ®Google Scholar
• Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millan S, et al. The renin-angiotensin system meets the hallmarks of cancer. JRAAS. 2015;16:227–233.
   Google Scholar
• Casselbrant A, Edebo A, Wennerblom J, et al. Actions by angiotensin II on esophageal contractility in humans. Gastroenterology. 2007;132:249–260.
   PubMed Web of Science ®Google Scholar
• Casselbrant A, Edebo A, Hallersund P, et al. Angiotensin II receptors are expressed and functional in human esophageal mucosa. Am J Physiol Gastrointestinal Liver Physiol. 2009;297:G1019–G1027.
   PubMed Web of Science ®Google Scholar
• Bjorkman E, Edebo A, Casselbrant A, et al. The renin-angiotensin system in the esophageal mucosa of healthy subjects and patients with reflux disease. Scand J Gastroenterol. 2013;48:147–159.
   PubMed Web of Science ®Google Scholar
• Bratlie SO, Edebo A, Casselbrant A, et al. The renin-angiotensin system in Barrett’s esophagus. Scand J Gastroenterol. 2016;51:1037–1042.
   PubMed Web of Science ®Google Scholar
• Sampliner RE. Practice Parameters Committee of the American College of G. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888–1895.
   PubMed Web of Science ®Google Scholar
• Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–255.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.
   PubMed Web of Science ®Google Scholar
• Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–1399.
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–472.
   PubMed Web of Science ®Google Scholar
• O'Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257–1264.
   PubMed Web of Science ®Google Scholar
• Du N, Feng J, Hu LJ, et al. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol Rep. 2012;27:1893–1903.
   PubMed Web of Science ®Google Scholar
• Wang W, Luo R, Lin Y, et al. Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome. Am J Physiol Renal Physiol. 2015;308:F910–F922.
   Google Scholar
• Zeki S, Fitzgerald RC. The use of molecular markers in predicting dysplasia and guiding treatment. Best Pract Res Clin Gastroenterol. 2015;29:113–124.
   PubMed Web of Science ®Google Scholar
• Du H, Liang Z, Zhang Y, et al. Effects of angiotensin II type 2 receptor overexpression on the growth of hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 2013;8:e83754.
   Google Scholar
• Taddei A, Fabbroni V, Pini A, et al. Cyclooxygenase-2 and inflammation mediators have a crucial role in reflux-related esophageal histological changes and Barrett's esophagus. Dig Dis Sci. 2014;59:949–957.
   PubMed Web of Science ®Google Scholar
• Ozgur T, Atik E, Hakverdi S, et al. The expressions of AMACR and iNOS in prostate adenocarcinomas. Pakistan J Med Sci. 2013;29:610–613.
   PubMed Web of Science ®Google Scholar
• Sonwalkar SA, Rotimi O, Scott N, et al. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase). Histopathology. 2010;56:900–907.
   PubMed Web of Science ®Google Scholar
• Taddei S, Bortolotto L. Unraveling the pivotal role of Bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16:309–321.
   PubMed Web of Science ®Google Scholar
• Ewert S, Laesser M, Johansson B, et al. The angiotensin II receptor type 2 agonist CGP 42112A stimulates NO production in the porcine jejunal mucosa. BMC Pharmacol. 2003;3:2.
   PubMedGoogle Scholar
• Jaiswal M, LaRusso NF, Nishioka N, et al. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res. 2001;61:6388–6393.
   PubMed Web of Science ®Google Scholar
• Vaninetti NM, Geldenhuys L, Porter GA, et al. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinogen. 2008;47:275–285.
   PubMed Web of Science ®Google Scholar
• Wang X, Lu J, Khaidakov M, et al. Delineation of the effects of angiotensin type 1 and 2 receptors on HL-1 cardiomyocyte apoptosis. Apoptosis. 2012;17:908–915.
   PubMed Web of Science ®Google Scholar
• Ager EI, Neo J, Nguyen L, et al. Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system. Journal of Gastroenterology and Hepatology 2016;31:1773–1782.
   PubMed Web of Science ®Google Scholar
• Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002;41:7–17.
   PubMed Web of Science ®Google Scholar
• Azizi M, Bissery A, Lamarre-Cliche M, et al. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension. 2004;43:785–790.
   PubMed Web of Science ®Google Scholar
• Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 2005;11:2686–2694.
   PubMed Web of Science ®Google Scholar